Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 11/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669415 | 0.91 | MAP3K12 (0.32) | MAP3K12 | |
| SCHEMBL1170436 | 0.78 | NPSR1 (0.34) | MAP3K12 | |
| SCHEMBL5528388 | 0.76 | ERCC1 (0.33) | MAP3K12PIK3CAMTOR | |
| SCHEMBL12225508 | 0.73 | MAP3K12 (0.34) | MAP3K12PIK3CAMTOR | |
| SCHEMBL14511045 | 0.73 | MAP3K12 (0.32) | MAP3K12 | |
| SCHEMBL14048388 | 0.73 | APOBEC3A (0.36) | — | |
| SCHEMBL1170192 | 0.73 | GRM5 (0.39) | — | |
| SCHEMBL12800455 | 0.72 | THRB (0.33) | MAP3K12 | |
| SCHEMBL1669275 | 0.71 | FAAH (0.39) | — | |
| SCHEMBL12225289 | 0.71 | MAP3K12 (0.34) | MAP3K12PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245241-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | MAP3K12 1425/4885PIK3CA 23/4885MTOR 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.